Diana N. Ionescu, MD, FRCP(C), FCAP
Medical Director Clinical Trials, BCCA VCC Laboratory
Clinical Professor, Department of Pathology and Laboratory Medicine, UBC
Dr. Ionescu is a graduate of University of Medicine and Pharmacy “Iuliu Hatieganu” in Cluj Napoca, Romania. She completed her postgraduate training in Anatomical and Clinical Pathology at the University of Pittsburgh Medical Center and a Fellowship in Gynecological Pathology at Vancouver General Hospital. She has practiced as a Consultant Pathologist at BC Cancer Agency in Vancouver since 2006. She is currently a Clinical Professor of Pathology at UBC and served as the residency program director for the Anatomic Pathology Residency Program between 2009 – 2017.
Her specific areas of diagnostic expertise are lung, gynecologic and breast pathology. She is an author of over 35 scientific publications and book chapters. She is the author and invited speaker at numerous regional, national and international lectures. Her investigation interests include oncologic pathology and molecular biomarkers, lung cancer and adult health education. She is the Canadian Anatomic and Molecular Pathology (CAMP) course director.
Dr. Ionescu is an enthusiastic advocate of pathologists participating in numerous patient education forums, TV shows, advocacy campaigns, being an Medical Advisor for Lung Cancer Canada and in 2015 appeared before the House of Commons Committee on Health.
Peter Black, B.Sc, M.D.
Senior Research Scientist, Vancouver Prostate Centre
Associate Director, Clinical Research, Vancouver Prostate Centre
Professor, Department of Urologic Sciences, University of British Columbia
Dr. Black is a surgeon scientist with clinical subspecialty interest in the treatment of urologic cancers, including especially bladder and prostate cancer. He maintains a grant-funded translational research program in urothelial carcinoma with a focus on genomic analysis of response to chemotherapy, mechanisms of resistance to chemotherapy, and novel targeted therapies for bladder cancer. One of his main laboratory projects relates to Notch signaling in bladder cancer. His group was the first to identify Notch2 as an oncogene in bladder cancer, and they are now working to elucidate differential regulation of these oncogenic properties of Notch2 compared to the tumor suppressive properties of Notch1, with the objective of modulate both pathways independently for therapeutic purposes.
Dr. Black is an active clinical trialist in his field and is study chair of the SWOG S1605 trial testing an immune checkpoint inhibitor in BCG-unresponsive high risk non-muscle invasive bladder cancer. He has authored >240 peer-reviewed publications and his scientific work has been published in >350 abstracts at national and international meetings. Dr. Black has acquired $12M in grant funding as PI or co-PI, in addition to contributing to infrastructure awards totaling $23M.
Dr. Black has many active collaborations, especially related to prostate imaging and image-guided robotic surgery. He works closely with Purang Abolmaesumi and Tim Salcudean in the UBC Department of Electrical and Computer Engineering, Piotr Kozlowski in Medical Physics, and Hongshen Ma in Mechanical Engineering. A long-standing collaboration with Decipher Biosciences has led to commercialization of a clinical grade genomic biomarker for muscle invasive bladder cancer.
Dr. Black has served as grant reviewer for multiple international funding agencies including Cancer Research UK, the Congressionally Directed Medical Research Program (CDMRP), and most of the main Canadian funding organizations. He is an ad hoc journal reviewer for >30 journals and has received awards for peer review from European Urology (2013 and 2018), Journal of Urology (2010, 2011, 2015) and Canadian Urological Association Journal (2016). He has served as assistant editor for Urologic Oncology and Associate Editor for both World Journal of Urology and European Urology Focus. In 2019 he became the founding editor-in-chief of the Society Internationale d’Urologie Journal.
Dr. Black has received a number of awards including Best Clinical Paper Published in Literature by the European Association of Urology (2016), the David A. Swanson Distinguished Alumnus Award from MD Anderson Cancer Center (2017) and the Distinguished Achievement Award for Excellence in Clinical or Applied Research by University of British Colombia Faculty of Medicine (2013). He has served on the Board of Directors of the Société Internationale d’Urologie (2013-2019) and is General Secretary of the International Bladder Cancer Network.
Gang Wang, MD, PhD, FRCPC
Consultant Pathologist, BC Cancer, Vancouver Center
Clinical Assistant, Professor of Pathology
University of British Columbia
Dr. Gang Wang earned his medical degree from the Tongji Medical College of Huazhong University of Science and Technology in China, and a PhD degree in Pathology and Laboratory Medicine from the University of British Columbia. After a couple of years of postdoc research, he started his residency in Case Western Reserve University in Cleveland for a year and returned to UBC to finish his training in Anatomic Pathology. After completing a Genitourinary Pathology fellowship in MD Anderson Cancer Center in Houston, Dr. Gang Wang came back to BC Cancer Vancouver Centre as a consultant pathologist.
Dr. Gang Wang’s research mainly focuses on malignancies of the genitourinary system. He is also interested in molecular biomarker studies in different tumors, including breast cancer and lung cancer.
Stephen Yip, MD, PhD, FRCPC
Neuropathologist, Vancouver General Hospital
Director – Cancer Genetics & Genomics Laboratory
Interim director – Centre for Clinical Genomics
Associate Professor of Medicine, University of British Columbia
Stephen Yip completed his MD-PhD training at UBC followed by 4/6 years of neurosurgery residency when he decided to switch to neuropathology. He did his fellowship training at the Massachusetts General Hospital under the mentorships of David Louis and John Iafrate. Stephen Yip is a contributor to the 2016 WHO Classification of CNS Tumours. In 2012, I discovered recurrent mutations in CIC in a majority of 1p19q-codeleted, IDH mutated oligodendroglioma. He is collaborating with Marco Marra in the Personalized OncoGenomics (POG) program of which he is the lead pathologist and is also branching out to practical epigenomics profiling of cancer and machine learning in glass- based pathology.
Kelly Zibrik, RN, MSc Nursing
Nurse Triage Coordinator, BC Cancer
Kelly Zibrik received her Bachelor in Science in Nursing degree from the University of British Columbia in 2002 and a Masters degree in Nursing from the University of Northern British Columbia in 2009. She has worked at the BC Cancer Agency since 2004 in various clinical nursing roles and is currently working as a nurse triage coordinator with the lung tumor group at the Vancouver Centre.